Ekso Bionics (NASDAQ:EKSO) Given New $1.00 Price Target at Lake Street Capital

Ekso Bionics (NASDAQ:EKSO) had its price objective reduced by investment analysts at Lake Street Capital from $2.00 to $1.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s target price indicates a potential upside of 128.31% from the stock’s previous close.

EKSO has been the topic of several other research reports. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Ekso Bionics in a report on Tuesday. StockNews.com assumed coverage on shares of Ekso Bionics in a report on Monday. They set a “hold” rating on the stock.

Ekso Bionics Trading Down 8.0 %

Ekso Bionics stock opened at $0.44 on Tuesday. Ekso Bionics has a 1 year low of $0.37 and a 1 year high of $1.64. The firm’s 50 day moving average price is $0.61 and its two-hundred day moving average price is $0.82. The firm has a market cap of $9.64 million, a price-to-earnings ratio of -0.67 and a beta of 1.46. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The company had revenue of $5.09 million during the quarter, compared to analyst estimates of $5.05 million. On average, research analysts predict that Ekso Bionics will post -0.48 EPS for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.